CAF vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is severely compromised, highlighted by a Piotroski F-Score of 1/9, indicating critical financial weakness. While the stock appears undervalued with a P/E of 4.44 and a growth-based intrinsic value of $29.05, these metrics are overshadowed by a bearish technical trend (10/100) and poor fundamental health. The disconnect between recent price gains and the underlying deterministic scores suggests a speculative rally rather than a fundamental recovery. Overall, the extreme weakness in the health scorecard outweighs the apparent value proposition.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CAF vs JPM: Head-to-Head Comparison
This page compares Morgan Stanley China A Share Fund, Inc. (CAF) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.